Ann Surg Treat Res.  2022 Jan;102(1):29-35. 10.4174/astr.2022.102.1.29.

Comparison of the healing effects of mesazaline and Ganoderma lucidum in acetic acid-induced colitis in rats

• Özden H
• Şahin Y
• Kilitçi A
• Karaca G
• Gömeç M
• Yildiz A
• Uçar C

• KMID: 2523767
• DOI: http://doi.org/10.4174/astr.2022.102.1.29

Abstract

Purpose
The etiology and pathogenesis of distal colitis (DC) are poorly understood. Activation of intestinal inflammatory response may lead to intestinal tissue necrosis. Antioxidant and anti-inflammatory agents are among the treatment options. Our study aimed to compare the protective effects of mesalazine and Ganoderma lucidum in acetic acid (AA)-induced colitis in rats.
Methods
Twenty-four rats were randomly grouped as colitis, mesalazine, G. lucidum, and combined (G. lucidum + mesalazine) groups. DC was induced by intrarectal administration of AA. Statistical comparisons were done by using parameters including colonic tissue IL-1, IL-6, TNF-α, and CRP levels. Histopathologic changes of the samples of colonic tissue were scored as mucosal damage score and inflammatory score. A P-value of <0.05 was considered significant.
Results
Intrarectal administration of AA leads to increased interleukin and CRP levels. High mucosal damage and inflammatory scores were noted in colitis group animals. Single mesalazine or G. lucidum treatment produced considerably decreased tissue interleukin and CRP levels. The lowest tissue interleukin and CRP levels were noted in the combined treatment group of animals. Mucosal damage and inflammatory scores were found to be significantly low in this group of animals.
Conclusion
The intrarectal administration of AA results in an activation of intestinal inflammation and severe mucosal damage in colonic tissue. Single use of mesalazine and G. lucidum treatment decreases the severity of intestinal inflammatory response and mucosal damage. The healing effects of the combined treatment of mesalazine and G. lucidum seem to be more effective than that of separate use in the treatment of DC.

Keyword

Acetic acid; Distal colitis; Ganoderma lucidum; Mesalazine

Figure

• 

  Fig. 1 Histopathologic changes in colon tissue (H&E, ×50). (A) Mild mucosal damage. (B) Severe mucosal damage.

Reference

1. Dieleman LA, Palmen MJ, Akol H, Bloemena E, Peña AS, Meuwissen SG, et al. Chronic experimental colitis induced by dextran sulphate sodium (DSS) is characterized by Th1 and Th2 cytokines. Clin Exp Immunol. 1998; 114:385–391. PMID: 9844047.

2. Vecchi M, Saibeni S, Devani M, Rondonotti E, De Franchis R. Review article: diagnosis, monitoring and treatment of distal colitis. Aliment Pharmacol Ther. 2003; 17 Suppl 2:2–6. PMID: 12786605.

3. Faramarzpour A, Tehrani AA, Tamaddonfard E, Imani M. The effects of crocin, mesalazine and their combination in the acetic acid-induced colitis in rats. Vet Res Forum. 2019; 10:227–234. PMID: 31737232.

4. Taghipour N, Molaei M, Mosaffa N, Rostami-Nejad M, Asadzadeh Aghdaei H, Anissian A, et al. An experimental model of colitis induced by dextran sulfate sodium from acute progresses to chronicity in C57BL/6: correlation between conditions of mice and the environment. Gastroenterol Hepatol Bed Bench. 2016; 9:45–52. PMID: 26744614.

5. Zhang Y, Chen D, Wang F, Li X, Xue X, Jiang M, et al. Comparison of the efficiency of different enemas on patients with distal ulcerative colitis. Cell Prolif. 2019; 52:e12559. PMID: 30659678.

6. Zhang FM, Li S, Ding L, Xiang SH, Zhu HT, Yu JH, et al. Effectiveness of mesalazine to treat irritable bowel syndrome: a meta-analysis. Medicine (Baltimore). 2019; 98:e16297. PMID: 31305414.

7. Wei B, Zhang R, Zhai J, Zhu J, Yang F, Yue D, et al. Suppression of Th17 cell response in the alleviation of dextran sulfate sodium-induced colitis by Ganoderma lucidum polysaccharides. J Immunol Res. 2018; 2018:2906494. PMID: 29888292.

8. Xie J, Liu Y, Chen B, Zhang G, Ou S, Luo J, et al. Ganoderma lucidum polysaccharide improves rat DSS-induced colitis by altering cecal microbiota and gene expression of colonic epithelial cells. Food Nutr Res. 2019; 63.

9. Koçak E, Akbal E, Taş A, Köklü S, Karaca G, Can M, et al. Anti-inf lammatory efficiency of Ankaferd blood stopper in experimental distal colitis model. Saudi J Gastroenterol. 2013; 19:126–130. PMID: 23680710.

10. Özden H, Karaca G. The healing effects of prp and thymoquinone on dss induced inflammatory bowel disease in rats. Ann Med Res. 2021; 28:1496–1499.

11. Shalkami AS, Hassan M, Bakr AG. Anti-inflammatory, antioxidant and anti-apoptotic activity of diosmin in acetic acid-induced ulcerative colitis. Hum Exp Toxicol. 2018; 37:78–86. PMID: 29187079.

12. Özden H, Karaca G, Bulut H, Niyaz M, Gömeç M, Daphan ÇE. The healing effects of the topical mesenchymal stem cells application on colonic anastomosis subjected to ischemia reperfusion injury. Kafkas Univ Vet Fak Derg. 2021; 27:595–600.

13. Mitchell CJ, Howarth GS, Chartier LC, Trinder D, Lawrance IC, Huang LS, et al. Orally administered emu oil attenuates disease in a mouse model of Crohn’s-like colitis. Exp Biol Med (Maywood). 2020; 245:1697–1707. PMID: 32903038.

14. Randhawa PK, Singh K, Singh N, Jaggi AS. A review on chemical-induced inflammatory bowel disease models in rodents. Korean J Physiol Pharmacol. 2014; 18:279–288. PMID: 25177159.

15. Kim JJ, Shajib MS, Manocha MM, Khan WI. Investigating intestinal inflammation in DSS-induced model of IBD. J Vis Exp. 2012; 1(60):3678.

16. Amirshahrokhi K. Febuxostat attenuates ulcerative colitis by the inhibition of NF-κB, proinflammatory cytokines, and oxidative stress in mice. Int Immunopharmacol. 2019; 76:105884. PMID: 31499267.

17. Soufli I, Toumi R, Rafa H, Touil-Boukoffa C. Overview of cytokines and nitric oxide involvement in immuno-pathogenesis of inflammatory bowel diseases. World J Gastrointest Pharmacol Ther. 2016; 7:353–360. PMID: 27602236.

18. Polat FR, Karaboğa I. Immunohistochemical examination of anti-inflammatory and anti-apoptotic effects of hesperetin on trinitrobenzene sulfonic acid induced colitis in rats. Biotech Histochem. 2019; 94:151–158. PMID: 30383440.

19. Tatiya-Aphiradee N, Chatuphonprasert W, Jarukamjorn K. Immune response and inflammatory pathway of ulcerative colitis. J Basic Clin Physiol Pharmacol. 2018; 30:1–10. PMID: 30063466.

20. Bevivino G, Monteleone G. Advances in understanding the role of cytokines in inflammatory bowel disease. Expert Rev Gastroenterol Hepatol. 2018; 12:907–915. PMID: 30024302.

21. Noguchi D, Wakita D, Tajima M, Ashino S, Iwakura Y, Zhang Y, et al. Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a T(h)17-independent manner. Int Immunol. 2007; 19:1431–1440. PMID: 17981790.

22. Waldner MJ, Neurath MF. Master regulator of intestinal disease: IL-6 in chronic inflammation and cancer development. Semin Immunol. 2014; 26:75–79. PMID: 24447345.

23. Mortensen JH, Manon-Jensen T, Jensen MD, Hägglund P, Klinge LG, Kjeldsen J, et al. Ulcerative colitis, Crohn’s disease, and irritable bowel syndrome have different profiles of extracellular matrix turnover, which also reflects disease activity in Crohn’s disease. PLoS One. 2017; 12:e0185855. PMID: 29028807.

24. Beigel F, Deml M, Schnitzler F, Breiteneicher S, Göke B, Ochsenkühn T, et al. Rate and predictors of mucosal healing in patients with inflammatory bowel disease treated with anti-TNF-alpha antibodies. PLoS One. 2014; 9:e99293. PMID: 24932476.

25. Cagin YF, Parlakpinar H, Vardi N, Polat A, Atayan Y, Erdogan MA, et al. Effects of dexpanthenol on acetic acid-induced colitis in rats. Exp Ther Med. 2016; 12:2958–2964. PMID: 27882101.

26. Pugliese N, Roda G, Peyrin-Biroulet L, Danese S. Emerging therapies for the treatment of ulcerative colitis. Expert Opin Emerg Drugs. 2020; 03. 09. DOI: 10.1080/14728214.2020.1737009. [Epub].

27. Williams C, Panaccione R, Ghosh S, Rioux K. Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease. Therap Adv Gastroenterol. 2011; 4:237–248.

28. Sehgal P, Colombel JF, Aboubakr A, Narula N. Systematic review: safety of mesalazine in ulcerative colitis. Aliment Pharmacol Ther. 2018; 47:1597–1609. PMID: 29722441.

29. Ahmad MF. Ganoderma lucidum: Persuasive biologically active constituents and their health endorsement. Biomed Pharmacother. 2018; 107:507–519. PMID: 30114634.

30. Liu C, Dunkin D, Lai J, Song Y, Ceballos C, Benkov K, et al. Anti-inflammatory effects of Ganoderma lucidum triterpenoid in human Crohn’s disease associated with downregulation of NF-κB signaling. Inflamm Bowel Dis. 2015; 21:1918–1925. PMID: 25993687.